Foundation Medicine Announces 2015 Third Quarter Results and Recent Highlights

Go back to Foundation Medicine Announces 2015 Third Quarter Results and Recent Highlights

Foundation Medicine (FMI) PT Lowered to $27 at Leerink Partners Amid Lower Forecast

November 4, 2015 7:49 AM EST

Leerink Partners analyst Dan Leonard lowered his price target on Foundation Medicine (NASDAQ: FMI) to $27.00 (from $36.00) while maintaining a Market Perform rating. The firm noted clinical volume was light and forecasts were reduced meaningfully.

Leonard commented, "FMI exceeded Street revenue expectations in the... More

Foundation Medicine (FMI) Misses Q3 EPS by 4c, Offers FY15 Guidance

November 3, 2015 4:01 PM EST

Foundation Medicine (NASDAQ: FMI) reported Q3 EPS of ($0.60), $0.04 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $24.04 million.

Foundation Medicine sees FY2015 revenue of $85-95 million, versus the consensus of $92.10 million.

For earnings... More